SPOTLIGHT -
Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis
Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.
Read More
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)